Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Another NASH Failure: Gilead’s Hits Keep Coming

Executive Summary

The failure of the STELLAR-3 trial of selonsertib had been widely anticipated following the failure in a sicker population in STELLAR-4.

You may also be interested in...



Gilead’s New O’Day Regime Has New R&D Structure

After several staff departures, Gilead consolidates its research arm under CEO oversight, while welcoming another Roche/Genentech alum. 

Biktarvy, PrEP Continue Driving Gilead’s HIV Dominance

HIV remains the main growth franchise for Gilead, despite an anticipated first quarter revenue downturn due to inventory and payer mix. Biktarvy’s launch and growth in PrEP business provide multiple drivers for the franchise.

Gilead Increasingly Seems Focused On Combo Therapy In NASH

At EASL, Gilead indicated it may not take any of its current NASH candidates forward as monotherapy options. Trial collaboration with Novo Nordisk may suggest pessimism toward selonsertib after Phase III disappointment.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125122

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel